Expression of neuroendocrine markers in meningeal and extrameningeal solitary fibrous tumors: a potential diagnostic pitfall
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F23%3A10466033" target="_blank" >RIV/00216208:11150/23:10466033 - isvavai.cz</a>
Alternative codes found
RIV/61383082:_____/23:00001273 RIV/00179906:_____/23:10466033 RIV/00023884:_____/23:00009616
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=MZ-ll4QlUg" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=MZ-ll4QlUg</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.humpath.2023.05.001" target="_blank" >10.1016/j.humpath.2023.05.001</a>
Alternative languages
Result language
angličtina
Original language name
Expression of neuroendocrine markers in meningeal and extrameningeal solitary fibrous tumors: a potential diagnostic pitfall
Original language description
Solitary fibrous tumors (SFTs) may show unusual morphologies, and in such circumstances, an unexpected immunoprofile can be misleading. Following an index case of myxoid meningeal SFT with a neuroendocrine immunoprofile, we decided to assess a neuroendocrine profile in SFTs from various locations. The cohort of 9 meningeal and 28 extrameningeal SFTs was evaluated for CNS WHO grade (G1-G3) and 4-tiered Demicco risk stratification. Immunohistochemical detection of sy-naptophysin, chromogranin, INSM1, CD56, and CD57 was performed in each case and semiquantita-tively assessed (0: no expression; 1+: <10% positive; 2+: 11e50%; and 3+: >51%); whole sections (meningeal SFTs) or tissue microarray (extrameningeal SFTs) were used for immunohistochemistry. The cohort included 13 men and 24 women. Meningeal SFTs included 5 WHO G1, 3 WHO G2, and 1 WHO G3 tumors. Extrameningeal SFTs included 21 low-risk, 4 intermediate-risk, and 2 high-risk tu-mors. INSM1 immunoreactivity was observed in 12 of 37 cases (32%; 8 cases 1+, 3 cases 2+, and 1 case 3+); synaptophysin was positive in 6 of 35 cases (19%; 5 cases 1+ and 1 case 2+); CD56 was positive in 20 of 37 cases (54%; 16 cases 1+, 3 cases 2+, and 1 case 3+); and CD57 was expressed in 14 of 36 cases (39%; 5 cases 1+, 4 cases 2+, and 5 cases 3+). Chromogranin positivity was not observed. No significant association was observed between expression of neuroendocrine markers and tumor grade, Demicco risk group or meningeal and extrameningeal location. Extrapleural SFTs showed a tendency for positivity of INSM1 (P = .014, c2) and CD57 (P = .017, c2) compared to pleural SFTs.& COPY; 2023 Elsevier Inc. All rights reserved.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30109 - Pathology
Result continuities
Project
<a href="/en/project/NU20-03-00360" target="_blank" >NU20-03-00360: Hypoxia-related therapeutic response in primary glioblastoma</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Human Pathology
ISSN
0046-8177
e-ISSN
1532-8392
Volume of the periodical
137
Issue of the periodical within the volume
JUN
Country of publishing house
US - UNITED STATES
Number of pages
6
Pages from-to
79-84
UT code for WoS article
001015457000001
EID of the result in the Scopus database
2-s2.0-85160512853